“The non-communicable disease [NCD] community always talks about the importance of prevention; many consider it the Holy Grail in the fight against NCDs. Why was it so hard to also accept treatment as part of the solution?” Princess Dina Mired, director general of the King Hussein Cancer Foundation in Amman, Jordan, asks in the Huffington Post “Impact” blog, noting only one target of the 2011 U.N. High-Level Meeting on NCDs “deals with treatment, the target on ‘essential medicines and basic technologies for treatment.'” She continues, “Treatment and prevention are heavily interrelated. The success of one is directly related to the other.” She adds, “A person in the developing world will not buy in to the importance of prevention if there is no treatment option available should that person get the disease.”
Programs, Funding & Financing
World Bank, Bangladeshi Government Sign Multi-Donor Trust Fund Agreement For Country's Health Sector
“On Wednesday, the World Bank and the Bangladeshi government signed a Multi-Donor Trust Fund Grant Agreement” under which “$280 million coming from the United States, Australia, the United Kingdom, and Sweden will go to the Bangladesh Health Sector Development Program, which aims to improve the health status of people in Bangladesh, particularly women, children and the marginalized,” the Devex “Development Newswire” reports. “The government will finance 75 percent of the program,” and “[t]he World Bank will also provide a $359 million credit through its anti-poverty arm, the International Development Association,” the news service writes (Ravelo, 9/13). “The program will focus on improving emergency obstetric and newborn care services and the nutritional status of expectant mothers and their children” and “will also strengthen health sector planning and resource management, human resources development, management of pharmaceuticals, health information systems and maintenance of health care facilities,” a World Bank press release states (9/12).
The board of the Global Fund to Fight AIDS, Tuberculosis and Malaria began a two-day meeting in Geneva on Thursday, “with one topic high on the agenda: a new funding model,” Devex’s “Development Newswire” reports. “The board will tackle aspects of a new funding model, which, according to Global Fund Director of Communications Seth Faison, ‘will change the way the Global Fund has made grants for 10 years,'” the news service writes, adding that the model, according to the International HIV/AIDS Alliance, “will see the Global Fund dropping its ’round’ grant-making process and replacing it with a ‘more flexible’ system.” In addition, “an ‘iterative dialogue process’ is also reportedly being explored,” Devex reports. “The proposed reforms seem good for the fund and its beneficiaries … [b]ut some have expressed their concerns on the funding model under consideration, specifically on the ‘historical disease application’ approach,” the news service writes (Ravelo, 9/13). According to an article on the Stop TB Partnership website, the new approach “would cap the proportion of funding available to tuberculosis (TB) projects at 16 percent,” and the proposal, “which is based on the proportion of grants awarded to TB in the past, met with strong objections from the community of people working on TB worldwide” (9/13).
Humanitarian Situation Better, Still Tenuous, In Zimbabwe As E.U. Scales Down Assistance, IRIN Reports
Though the number of people in Zimbabwe in need of food aid has dropped from seven million in 2002-2003 to one million currently, the number could still rise by 600,000 in 2013, IRIN reports in an analysis of the humanitarian and political situation in the country. “Still, two of the country’s biggest donors, the European Union and the U.S., and their implementing partner, the U.N., say Zimbabwe is on its way to recovery and development,” the news service writes, noting “[t]he E.U. has announced that it is scaling down its humanitarian assistance.” IRIN states, “The E.U. has moved from funding only emergency food aid to funding nutrition, health, water and sanitation, and protection programs. [U.N. Financial Tracking Service (FTS)] data show that the health and education sectors are better funded than last year, but agriculture programs are worse off.”
“As many as 200 million children across the world fail to reach their full potential because their early brain development is held back by poverty, disease and malnutrition, global health experts said on Thursday,” Reuters reports (Kelland, 9/13). The Canadian government-funded Grand Challenges Canada on Thursday “announced $11.8 million CAD [$12 million] in funding over two years for 11 bold ideas from innovators in the developing world, to address health conditions causing diminished cognitive potential and stunting,” according to a Grand Challenges Canada press release (9/13). The projects, which will be implemented in developing countries such as Thailand, Pakistan, Bangladesh, and Colombia, “include plans to encourage so-called ‘kangaroo mother care,’ where low-weight newborns are held skin to skin rather than put into incubators, and ways of combating maternal depression to boost interaction between mothers and babies,” Reuters notes (9/13).
After testing about 5,600 existing medications for their effectiveness against drug-resistant strains of tuberculosis (TB), researchers from Weill Cornell Medical College reported this week in the Proceedings of the National Academy of Sciences that oxyphenbutazone, “an anti-inflammatory medication marketed in the 1950s as Tandearil and still used in veterinary medicine,” killed both latent and active TB bacteria in test-tube experiments, the Los Angeles Times’ “Booster Shots” blog reports. The medication is inexpensive, estimated to cost two cents per day in developing countries, according to the researchers, but it needs to go through “a series of clinical trials in which researchers would flesh out, in a human population, the medication’s safety and effectiveness record at various doses, in different patient populations and at different stages of the disease,” the blog writes.
Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), and Kate McQueston, a program coordinator at CGD, write in the center’s “Global Health Policy” blog that a reduction in AIDS funding to Ethiopia from PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria “might be warranted due to epidemiological trends and improved efficiency, or might cripple progress as health programs dependent on external donors are cut back,” but “with the current poor status of basic information on beneficiaries and costs, it’s difficult to judge whether these cuts are good or bad.” They outline the history of AIDS funding in Ethiopia, posit what future funding might encompass, and say additional information is needed from PEPFAR, the Global Fund, and the Ethiopian government in order to know the true impacts of reduced funding (9/11).
Pending Cases Against India's Patent Laws Threaten Public Health, Misinterpret International IP Agreements, Report Says
“Pending cases against India’s patent laws threaten public health and misinterpret international intellectual property (IP) agreements,” researchers from Queen Mary, University of London argue in a special report published online in the Lancet on Monday, PharmaTimes reports (Taylor, 9/11). “The report highlights legal challenges by two pharmaceutical companies, Bayer and Novartis, to key provisions of India’s Patents Act,” a university press release notes, adding, “Bayer’s appeal was heard last week, and the Indian Supreme Court is due to hear Novartis’ appeal on 11 September.”
Devex News Analysis Examines Democratic, Republican Party Platforms On Foreign Policy, Including Global Health
A Devex news analysis examines the Democratic and Republican platform positions on foreign policy following the party conventions, writing, “Even as pocketbook concerns continue to overshadow foreign policy issues on the campaign trail, in both Charlotte and Tampa, top-billed speakers made the case for the U.S. foreign aid program.” The article examines the core principles of each platform, notes that neither platform offers specifics on foreign aid spending, and discusses the platforms’ stances on certain foreign policy issues, including global health, food security, climate change, and gay rights.
The Australian Agency for International Development (AusAID) “is planning to boost support for medical research, technology and innovations,” as well as “encourage collaboration and capacity building aimed at poverty-related and neglected tropical diseases,” SciDev.Net reports. The agency’s draft Medical Research Strategy for the Pacific “outlines how AusAID will support research both at the ‘preventative end and at the curative end’ to create new medical products such as diagnostics, drugs or vaccines, and to improve the clinical treatment of people in poor communities” and “says there are hardly any financial incentives for commercial investment in diseases affecting the poor, who bear the biggest burden of disease,” according to the news service. “The strategy fits within the Australian government’s overall policy of making aid more effective,” SciDev.Net states, noting an AusAID spokesperson based in Canberra said, “Practical research will help inform where and how the resources of Australia and its partners can be most effectively and efficiently deployed” (Jackson, 9/10).